grade III prostatic intraepithelial neoplasia
diseaseOn this page
Also known as adenocarcinoma in situ of prostateadenocarcinoma in situ of the prostatecarcinoma in situ of prostatecarcinoma in situ of prostate glandgrade 3 pingrade 3 prostatic intraepithelial neoplasiagrade III pinPIN IIIprostate adenocarcinoma in situprostate carcinoma in situprostate gland carcinoma in situprostate gland in situ carcinomastage 0 prostate gland carcinoma
Summary
grade III prostatic intraepithelial neoplasia (MONDO:0006234) is a disease. A subtype of in situ carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | grade III prostatic intraepithelial neoplasia |
| Mondo ID | MONDO:0006234 |
| EFO | EFO:1000283 |
| DOID | DOID:8634 |
| ICD-10-CM | D07.5 |
| NCIT | C3642 |
| SNOMED CT | 92691004 |
| UMLS | C5200982 |
| MedGen | 1684800 |
| Anatomy (UBERON) | UBERON:0002367 |
| Is cancer (heuristic) | no |
Also known as: adenocarcinoma in situ of prostate · adenocarcinoma in situ of the prostate · carcinoma in situ of prostate · carcinoma in situ of prostate gland · grade 3 pin · grade 3 prostatic intraepithelial neoplasia · grade III pin · PIN III · pin III · prostate adenocarcinoma in situ · prostate carcinoma in situ · prostate gland carcinoma in situ · prostate gland in situ carcinoma · stage 0 prostate gland carcinoma
Disease family
This is a subtype of in situ carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › in situ carcinoma › grade III prostatic intraepithelial neoplasia
Related subtypes (20): oral cavity carcinoma in situ, pharynx carcinoma in situ, gall bladder carcinoma in situ, adenocarcinoma in situ, nasal cavity carcinoma in situ, skin carcinoma in situ, breast carcinoma in situ, eye carcinoma in situ, lung carcinoma in situ, squamous carcinoma in situ, larynx carcinoma in situ, intestine carcinoma in situ, bladder carcinoma in situ, esophagus carcinoma in situ, uterus carcinoma in situ, liver carcinoma in situ, stomach carcinoma in situ, kidney carcinoma in situ, carcinoma in situ of ureter, carcinoma in situ of urethra
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.